

Alice Huertas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1698903/publications.pdf>

Version: 2024-02-01

47
papers

3,333
citations

201658

27
h-index

265191

42
g-index

48
all docs

48
docs citations

48
times ranked

4459
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation in Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 210-221.	0.8	333
2	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	6.7	284
3	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 3207-3218.	8.2	208
4	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle-“Like Cells in Pulmonary Hypertension. <i>Circulation</i> , 2014, 129, 1586-1597.	1.6	178
5	C-Kit-Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 116-123.	5.6	176
6	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. <i>European Respiratory Review</i> , 2013, 22, 543-551.	7.1	172
7	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 983-997.	5.6	144
8	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1332-1340.	1.6	141
9	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>Chest</i> , 2015, 147, 529-537.	0.8	140
10	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	6.7	136
11	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1956-1970.	8.2	125
12	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 895-904.	6.7	110
13	Activation of TNFR1 ectodomain shedding by mitochondrial Ca ²⁺ determines the severity of inflammation in mouse lung microvessels. <i>Journal of Clinical Investigation</i> , 2011, 121, 1986-1999.	8.2	89
14	A Critical Role for p130 ^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 666-676.	5.6	85
15	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 124, 846-855.	4.5	81
16	COPD: a multifactorial systemic disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2011, 5, 217-224.	2.6	78
17	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020, 116, 885-893.	3.8	70
18	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 149, 1482-1493.	0.8	63

#	ARTICLE	IF	CITATIONS
19	Leptin signalling system as a target for pulmonary arterial hypertension therapy. <i>European Respiratory Journal</i> , 2015, 45, 1066-1080.	6.7	62
20	Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. <i>Journal of Applied Physiology</i> , 2010, 109, 60-67.	2.5	58
21	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 189-196.	5.6	54
22	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020, 116, 686-697.	3.8	54
23	Dasatinib increases endothelial permeability leading to pleural effusion. <i>European Respiratory Journal</i> , 2018, 51, 1701096.	6.7	50
24	Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. <i>Respiratory Physiology and Neurobiology</i> , 2010, 170, 23-31.	1.6	47
25	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 766-782.	2.4	44
26	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 872-881.	0.8	43
27	Pulmonary veno-occlusive disease: advances in clinical management and treatments. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 217-231.	2.5	41
28	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	6.7	28
29	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 219-231.	0.8	26
30	Platelets Enhance Endothelial Adhesiveness in High Tidal Volume Ventilation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 569-575.	2.9	24
31	Erythrocytes Induce Proinflammatory Endothelial Activation in Hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 48, 78-86.	2.9	23
32	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021, 117, 1391-1401.	3.8	23
33	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019, 33, 3670-3679.	0.5	22
34	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018, 52, 1800272.	6.7	21
35	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2725-2736.	6.4	20
36	The Thousand Faces of Leptin in the Lung. <i>Chest</i> , 2021, 159, 239-248.	0.8	18

#	ARTICLE	IF	CITATIONS
37	New targets for pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 377-385.	2.6	16
38	Pharmacokinetic evaluation of continuous intravenous epoprostenol. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1587-1598.	3.3	15
39	Platelets induce endothelial tissue factor expression in a mouse model of acid-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012, 302, L1209-L1220.	2.9	13
40	Circulating fibrocytes and pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 39, 210-212.	6.7	8
41	Circulating CD34+ Cells Are Decreased in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 537-538.	3.5	7
42	A study of magnesium deficiency in human and experimental pulmonary hypertension. <i>Magnesium Research</i> , 2012, 25, 21-27.	0.5	2
43	Pirfenidone protects against pulmonary hypertension in the Sugden5416/hypoxia rat model. , 2018, , .		1
44	Red blood cell-induced proinflammatory lung endothelial signaling in hypoxia. <i>FASEB Journal</i> , 2009, 23, 1023.4.	0.5	0
45	Airway acid instillation promotes procoagulant lung endothelial mechanisms in mouse. <i>FASEB Journal</i> , 2009, 23, 1023.5.	0.5	0
46	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. <i>Pancreatic Islet Biology</i> , 2015, , 241-256.	0.3	0
47	Uric acid contributes to the progression of pulmonary hypertension in rodents and humans. , 2018, , .		0